INTRODUCTION

This activity covers management strategies for treating PsA along with 4 patient case studies.

Launch Date: October 6, 2022, 2022
Release Date: September 27, 2022
Expiration Date: August 31, 2023

TARGET AUDIENCE

Talking PsA activities are designed for healthcare providers who actively treat/manage patients with psoriatic arthritis. Activities are intended for physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists.

LEARNING OBJECTIVES

Upon completion of this enduring material, participants should be able to:

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

• There are no fees for participating in and receiving credit for this activity.
• Review the activity objectives and CME/CE information.
• Review all modules associated with this course.
• Successfully complete the post-test ( accuracy).
• Complete the CME/CE evaluation.
• The estimated time to complete this activity is hour.
• Upon successful completion, your AMA/ANCC certificate will be emailed to you. ACPE credit will be submitted to Rush University Medical Center and posted to CPE Monitor.

ACCREDITATION STATEMENTS

Participation in the entire knowledge-based activity is required to obtain a certificate. This activity is being presented without bias and with commercial support.

RESOLUTION OF CONFLICT OF INTEREST

In accordance with the ACCME Standards for Commercial Support of CME, the Rush University Medical Center and Practice Point Communications will implement mechanisms, prior to the planning and implementation of this CME/CE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CE activity.

DISCLOSURE

Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices.  Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

It is the policy of the Rush University Center for Innovative and Lifelong Learning to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE.  All individuals who have the ability to control or influence the content of an educational activity must disclose information about all of their financial relationships with ineligible companies within the prior 24 months.  There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies.  Individuals must disclose regardless of their view of the relevance of the relationship to the education.  Those who must disclose include (but are not limited to) members of the Planning Committee, speakers, presenters, authors, and/or content reviewers.  All information disclosed must be mitigated and then shared with the participants/learners prior to the start of the educational activity.

Individuals in control of content for this activity have the following relevant financial relationships to disclose and all financial relationships have been mitigated.

DISCLOSURES

The speakers and planning committee members listed below have stated they have no significant relationships to disclose.
Sally Lemke, DNP, WHNP-BC
Jennifer Comerford
Julia Peterson
Peter Pinkowish
Amber Kujath, PhD, RN, ONC

The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information they planned and/or present is done so fairly and without bias:

FACULTY DISCLOSURES

Philip Mease, MD
Industry funded research/investigator: AbbVie, Affibody, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, Gilead Sciences, GlaxoSmithKline, Inmagene, Janssen, Lilly, Merck, Novartis, Pfizer, SUN Pharma, UCB
Consultant: AbbVie, Affibody, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, Gilead Sciences, GlaxoSmithKline, Inmagene, Janssen, Lilly, Merck, Novartis, Pfizer, SUN Pharma, UCB
Speakers’ bureau, faculty, peer reviewer: AbbVie, Affibody, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, Gilead Sciences, GlaxoSmithKline, Inmagene, Janssen, Lilly, Merck, Novartis, Pfizer, SUN Pharma, UCB

Joseph F. Merola, MD
Industry funded research/investigator: Abbvie, Amgen, Bayer, Biogen, Dermavant, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi-Regeneron, UCB
Consultant: Abbvie, Amgen, Bayer, Biogen, Dermavant, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi-Regeneron, UCB

DISCLAIMER

The Rush University Medical Center and Practice Point Communications present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The Rush University Medical Center and Practice Point Communications assume no liability for the information herein.

PRIVACY POLICY

The Rush University Medical Center and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The Rush University Medical Center and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME, ANCC, or ACPE.

Rush University Medical Center and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

COPYRIGHT INFORMATION

Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:

The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.

HARDWARE/SOFTWARE REQUIREMENTS

• Hardware: A minimum of 512MB of RAM and a Pentium IV CPU for Intel-based hardware & PowerPC G4 or above for MAC.
• Graphics/Monitor: A color monitor capable of a minimum of 1024 x 768 pixel resolution.
• Network: An Internet connection with 1Mbps available download & 256kbps bandwidth.

• Windows 7 or above running Internet Explorer 10 or above.
• MAC OSX 10.5 (Leopard) or above running Safari 6 or above, or any version of Chrome, Firefox or Opera published in the last two years.
• A recent version of a Linux distribution or FreeBSD running Chrome v13, Opera 11.5, Firefox 5.0.1, or Epiphany 3.0.4 or above.

• Any Apple iPad or iPad Mini running iOS 7.1 or above.
• Android tablets such as the Kindle Fire or Samsung Galaxy S.

COMMERCIAL SUPPORT ACKNOWLEDGMENT